U.S. Insurance Stock News

Earlier in January, Edwards Lifesciences said a U.S. court granted the FTC’s request to block its planned acquisition of JenaValve, while the company continued to highlight progress in transcatheter therapies such as its SOJOURN aortic regurgitation valve and the JOURNEY pivotal trial. Against this legal setback, Edwards’ growing body of long-term clinical data and portfolio advances in minimally invasive heart valves underscore its focus on underserved structural heart patients. We’ll now...

International Seaways recently highlighted its cybersecurity focus as Global CISO Amit Basu presented at the 8th Annual Global Cyber Future Dialogue 2026 in Davos, Switzerland. The appearance underscores how a crude and product tanker owner is increasingly positioning cyber resilience as a core part of its operating profile, alongside its shipping operations. We’ll now examine how this heightened emphasis on cybersecurity, alongside favorable tanker market conditions, shapes International...

Plug Power (NasdaqCM:PLUG) has launched a major restructuring under "Project Quantum Leap", including cost cuts, staff reductions, and facility consolidations. The company is preparing for a leadership transition, with Andy Marsh moving to Executive Chairman and Jose Luis Crespo set to become CEO. Shareholders are being asked to approve an increase in authorized shares, with a reverse stock split presented as a potential fallback if the vote does not pass. Plug Power sits at a critical...

HomeTrust Bancshares FY 2025 Earnings Snapshot HomeTrust Bancshares (HTB) has posted its FY 2025 results with fourth quarter revenue of US$51.5 million and EPS of US$0.95, while trailing twelve month revenue came in at US$206.1 million and EPS at US$3.79, supported by net income of US$64.4 million over that period. The company reported quarterly revenue increasing from US$47.7 million in Q3 FY 2024 to US$51.5 million in Q4 FY 2025, with EPS over that same span ranging between US$0.77 and...

Phase 3 lymphoma data puts AbbVie (ABBV) oncology in focus AbbVie (ABBV) is drawing fresh attention after reporting Phase 3 results for epcoritamab in relapsed or refractory diffuse large B cell lymphoma, with the bispecific antibody improving progression free survival versus chemoimmunotherapy. See our latest analysis for AbbVie. Against this backdrop, AbbVie’s 1 day share price return of 0.91% and 7 day return of 0.63% sit alongside a softer 30 day share price return of a 4.67% decline and...

Biogen Inc. recently received European Commission marketing authorization for a new high dose regimen of SPINRAZA (nusinersen) to treat 5q spinal muscular atrophy, updating the therapy’s European Union label with an accelerated loading phase and modified maintenance dosing schedule. This approval is underpinned by the DEVOTE Phase 2/3 data showing statistically significant motor function improvements versus a matched untreated group, potentially enhancing SPINRAZA’s clinical profile and...

Trane Technologies (TT) is back on watch for investors after recent trading left the shares with a mixed return profile over the past month and past 3 months, alongside continued profitability. See our latest analysis for Trane Technologies. With the share price at $390.13, Trane Technologies has seen mixed momentum, with a 7 day share price return of 0.74% against a 90 day share price return of an 8.39% decline, while the 5 year total shareholder return of 191.78% contrasts with a softer 1...

Western Union (WU) is pushing further into digital finance with plans for a U.S. dollar stablecoin on the Solana blockchain, drawing fresh attention to a stock still tied to a shrinking legacy transfer business. See our latest analysis for Western Union. At a share price of US$9.41, Western Union has had a steady but muted run recently, with a 4.91% 3 month share price return and a 5 year total shareholder return of 40.78% decline. This suggests any excitement around the stablecoin plan is...

Wondering if Bio-Rad Laboratories at around US$305 a share is starting to look like value, or if the recent price action is a warning sign you should not ignore? The stock has been volatile, with a 5.2% decline over the last week, a 1.4% gain over the past month, and longer term returns of a 13.4% decline over 1 year, 35.9% decline over 3 years, and 46.1% decline over 5 years. These moves sit against a backdrop of ongoing interest in life sciences and diagnostics. In this space, investors...

OFG Bancorp (OFG) closed out FY 2025 with fourth quarter revenue of US$152.4 million and EPS of US$1.26, while trailing twelve month revenue came in at US$623.9 million and EPS at US$4.63. Over recent periods, revenue has ranged from US$152.5 million in Q4 2024 to US$160.7 million in Q2 2025, with quarterly EPS moving from US$1.10 in Q4 2024 to US$1.26 in Q4 2025 and trailing net income reaching US$205.1 million. This context frames how investors may look at the bank’s approach to managing...

If you are wondering whether Plexus at around US$181 per share still offers value or is getting ahead of itself, you are not alone. The stock has recent returns of 0.9% over 7 days, 17.9% over 30 days, 19.1% year to date, 18.2% over 1 year, 93.1% over 3 years and 131.7% over 5 years, which can change how investors think about both upside and risk. Recent news coverage has focused on Plexus as an established player in the tech and electronics manufacturing space, with attention on how its...

Institutional Shareholder Services (ISS) has recommended that shareholders approve Kimberly-Clark’s proposed $40b acquisition of Kenvue (NYSE:KVUE). The endorsement comes while Kenvue faces ongoing litigation and product safety questions linked to parts of its consumer health portfolio. ISS’s view is expected to be influential ahead of the upcoming shareholder vote on the deal. Kenvue, the consumer health company behind a range of over the counter and personal care brands, sits at the...

Nike (NKE) is in focus after new CEO Elliott Hill pushed a Win Now turnaround, reshaping leadership in key regions and leaning back into sports performance and wholesale partnerships to address recent stock and margin pressures. See our latest analysis for NIKE. NIKE's recent "Win Now" reset, leadership changes and focus on performance and wholesale come after a challenging stretch, with the share price at US$65.46 and a 1 month share price return of 14.16% contrasting with a 1 year total...

If you are wondering whether Broadcom's current share price still makes sense, this article walks through what that price could imply about value and where the gaps in the story might be. The stock is currently at US$325.49, with a 7 day return of 5.1% decline, a 30 day return of 6.8% decline, a year to date return of 6.4% decline, a 1 year return of 36.7% and a very large 3 year and 5 year return, around 7x over 5 years. Recent interest around Broadcom has been driven in part by its role...

Fourth quarter earnings and buyback completion come into focus Northern Trust (NTRS) has just reported fourth quarter and full year 2025 results, alongside completing a sizable share repurchase tranche, giving investors fresh data on profitability, net interest income and capital returns. See our latest analysis for Northern Trust. The latest earnings, dividend declarations and completion of the buyback appear to have coincided with stronger sentiment, with a 1 day share price return of 6.02%...

First Bancorp (FBNC) has wrapped up FY 2025 with fourth quarter revenue of US$79.2 million and basic EPS of US$0.38, alongside trailing twelve month revenue of US$378.8 million and EPS of US$2.68 that sit against a reported 46.5% year over year earnings rise. Over the past few quarters, the company has seen revenue move from US$65.2 million in Q4 2024 to US$79.2 million in Q4 2025, while quarterly EPS shifted from US$0.09 to US$0.38 as higher trailing net profit margins framed a more...

Immunovant recently reported encouraging past clinical progress for its lead FcRn-targeting antibody IMVT-1402 in autoimmune disease trials, while analysts reiterated positive views on the company’s pipeline. This combination of supportive trial updates and favorable analyst commentary has sharpened attention on IMVT-1402’s potential to reshape treatment options across multiple autoimmune indications. We’ll now examine how this renewed focus on IMVT-1402’s autoimmune potential influences...

Meta Platforms (NasdaqGS:META) has appointed Dina Powell McCormick as President and Vice-Chairman. Powell McCormick will oversee AI infrastructure efforts, aligning leadership, policy and large scale AI investment. The appointment brings together her global finance and U.S. government experience at a time of heavy AI focus for Meta. Meta Platforms, trading at $647.63, comes into this leadership change with very large 3 year returns and a value score of 5. The stock is up 4.3% over the past...

In recent weeks, SLB has completed the acquisition of RESMAN Energy Technology, secured a five-year stimulation services contract with Aramco in Saudi Arabia’s unconventional gas fields, and partnered with Archer on an integrated plug and abandonment contract for Equinor’s Titan platform in the Gulf of America. Together, these moves deepen SLB’s capabilities in digital reservoir monitoring and long-cycle offshore work while reinforcing its role in energy transition applications such as CO₂...

Sirius XM Holdings (NasdaqGS:SIRI) is reporting ongoing subscriber losses as competition from internet streaming platforms intensifies. Streaming services such as Spotify and Apple are attracting listeners away from satellite radio, raising questions about Sirius XM's long term business model. The subscriber trend is drawing attention to the company’s ability to support its revenue base and manage its debt load. Sirius XM runs a subscription based satellite radio business focused on in car...

If you are wondering whether Apollo Global Management is attractively priced or starting to look expensive at around US$139.73, this article walks you through what the current share price might mean for you. The stock has seen a 3.1% decline over the last 7 days, a 5.8% decline over 30 days, and a 4.7% decline year to date. It still sits on a 5-year return of 225.6% and a 3-year return of 108.9%. These figures can influence how investors think about both potential upside and risk. Recent...

CACI International (CACI) has just posted Q2 2026 results that included total revenue of US$2.2b and basic EPS of US$5.61, alongside trailing twelve month revenue of US$9.0b and EPS of US$23.47. Over the past few quarters, the company has seen revenue move from US$2.1b in Q2 2025 to US$2.3b in Q4 2025 and EPS range between US$4.90 and US$7.18, giving investors a clearer view of how recent profit trends compare with the latest quarter. With a trailing net margin sitting in the mid single...

In January 2026, Monarch Financial Technology Solutions expanded its partnership with Intapp, agreeing to resell the DealCloud platform and provide accelerated deployment support to private capital market clients. This deeper collaboration effectively turns Monarch into both a distribution and implementation partner, highlighting how service ecosystems can be central to technology adoption in complex professional markets. Next, we’ll examine how Monarch’s new role as a DealCloud reseller...

Workday (WDAY) has put a C$1b commitment on the table for its Canadian operations over the next five years, putting a spotlight on how this plan might influence the stock’s appeal for investors. See our latest analysis for Workday. The Canada commitment arrives after a stretch of weaker momentum, with the 30 day share price return of 12.65% and year to date share price return of 8.56% both in decline. At the same time, the 1 year total shareholder return of 26.29% contrasts with a modest 3...